NASDAQ: COGT

Cogent Biosciences (COGT) Stock Analysis & Forecast

Nov 13 close

$28.56−0.58 (−2.0%)

Gekko Brief

AI summaryNov 9 close

Cogent Biosciences reported third-quarter 2026 financial results this week, highlighting preparations for the anticipated launch of bezuclastinib in GIST and other systemic mastocytosis indications, alongside a wider quarterly net loss of $111.4 million, up from $80.9 million a year prior, driven by increased research and development and general and administrative expenses. The company also disclosed $791 million in cash and securities. Separately, HC Wainwright & Co. maintained its Buy rating and raised its price target to $56 from $55, and a DCF-based analysis suggested the stock could be significantly undervalued relative to estimated future cash flow value.

COGT closed at $33.54, up 6% on the day, with the stock sitting between its 50-day average of $31.80 and 200-day average of $35.47. The GekkoIndex reads 54.2, placing the stock in the Neutral zone. Price sits 12.1% below Gekko Fair Value of $38.14. One-month returns stand at 8.2%, while three-month returns are -13.3%, and the stock's 52-week range spans $13.93 to $43.73.

The next earnings date falls on 16 February 2027, 93 days away, outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity in the respective windows is noted in current signals. Analyst sentiment skews heavily positive, with 8 of 9 firms rating the stock Buy and a consensus target of $55.82, implying 66.4% consensus upside. Seasonality data shows the next 20 trading days have averaged a 31.8% return over 5 years, rising in 3 of those years, a pattern worth noting given the stock's typical 20-day move of 11.5%.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Cogent Biosciences price vs fair value

$37.57$28.56Nov ’25May ’26Nov ’26
Close $28.56200-day averageGekko Fair Value $37.57

Cogent Biosciences quick facts

Market cap
$4.97B
P/E ratio
—
Forward P/E
—
EPS, TTM
−$2.26
Revenue, TTM
$0
Profit margin
0%
Dividend yield
—
Beta
0.34
Volume
1.15M avg 2.10M
1-year return
−19.0%
Typical daily move
±6.5%
Typical 20-day move
±11.5%
50-day average
$31.39
200-day average
$35.30
Next earnings
Feb 16
Shares outstanding
174.0M
52-week range
$27.74$43.73

Cogent Biosciences swing-trade checklist

Cogent Biosciences scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive0 mixed2 headwinds

  • Trendheadwind

    Below 50 and 200-day

    Close $28.56 is below the 50-day ($31.39) and 200-day ($35.30) averages, and the 50-day is below the 200-day.

    See the chart
  • GekkoIndexsupportive

    63.4, Accumulation

    Reading 63.4 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    24.0% below

    Price is 24% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 93 days

    Next report Feb 16, 2027, 93 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −12.5% on average

    From this point in the calendar, the next 20 trading days averaged −12.5% over 5 years, rising in 1 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Cogent Biosciences stock chart and price history

Cogent Biosciences closed at $28.56 on Nov 13, 2026, −19.0% over the past year, inside a 52-week range of $27.74 to $43.73.

Close50-day average200-day averageVolume
Cogent Biosciences share price, past year, with 50-day and 200-day moving averages and volume$10$20$40DecJan 2026FebMarAprMayJunJulAugSepOctNov28.56

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−3.2%
3 months
−24.6%
6 months
−12.6%
1 year
−19.0%
The full COGT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open COGT in Gekko

Follow Cogent Biosciences through every session

Put COGT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track COGT in GekkoFree for 7 days. No credit card required.

About Cogent Biosciences

Cogent Biosciences develops medicines aimed at diseases caused by specific genetic mutations. Its lead candidate is a selective tyrosine kinase inhibitor designed to target the KIT D816V mutation linked to systemic mastocytosis, as well as other KIT exon 17 mutations found in patients with advanced gastrointestinal stromal tumors. This mutation-targeted drug candidate is the focus most associated with the company.

The company works under a licensing arrangement with Plexxikon Inc. that gives it the ability to research, develop, and commercialize this compound, known as bezuclastinib. Cogent Biosciences was formerly named Unum Therapeutics Inc. before it took on its present name in October 2020.

Founded in 2014, Cogent Biosciences is based in Cambridge, Massachusetts. Its shares trade on the NASDAQ under the ticker COGT.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
cogentbio.com

Cogent Biosciences GekkoIndex: the smart money zone

Cogent Biosciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 63.4, in the Accumulation zone, up 5 points over five sessions.

010063.4Accumulation

Up 5 points over five sessions, from the Neutral zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying38+1.5%+4.1%+6.9%+16.6%
Accumulation (current zone)203+2.9%+4.3%+6.1%+16.3%
Neutral395+1.5%+4.4%+10.1%+25.7%
Distribution59+4.7%+4.9%+8.0%+28.1%
Selling7Too few readings yet

Average COGT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the COGT price, zone by zone.Track COGT in Gekko

Is Cogent Biosciences stock overvalued? Gekko Fair Value

Cogent Biosciences trades 24.0% below Gekko Fair Value of $37.57, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Cogent Biosciences shares are worth, recalculated every trading day.

$37.57

Gekko Fair Value, Nov 14, 2026

24.0% Undervalued

At the end of Aug 2026 the price was 30.4% below the estimate.

Gekko Fair ValueShare price, month end
$38$29Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open COGT in Gekko

Cogent Biosciences insider and Congress trading

No open-market insider purchases were filed for Cogent Biosciences, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for COGT in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every COGT insider filing, plotted on the chart in Gekko.Open COGT in Gekko

Congress trades last 90 days

No trades in COGT were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for COGT, plotted on the chart in Gekko.Open COGT in Gekko

Hedge funds and billionaires quarter ended Mar 31

0of the funds Gekko tracks hold COGT.

0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

Cogent Biosciences earnings: next date and track record

Cogent Biosciences reports on Feb 16, 2027 (93 days away), and beat the EPS estimate in 4 of its last 8 reports.

4 of 8reports beat the EPS estimate
±21.4%average move across the report
2 of 8reports followed by a gain

Share-price move across each report

0.0%Nov ’24−10.1%Feb ’25−15.3%May ’25−9.0%Aug ’25+120.5%Nov ’25+5.0%Feb ’26−2.3%May ’26−8.7%Aug ’26
ReportedEPSSurpriseRevenueSurpriseMove
Aug 10, 2026−$0.52
est −$0.55
+6.3%—
est $1K
—−8.7%
May 5, 2026−$0.53
est −$0.53
0.0%—
est $500
—−2.3%
Feb 17, 2026−$0.55
est −$0.51
−7.8%—
est $1.68M
—+5.0%
Nov 7, 2025−$0.50
est −$0.54
+7.4%——+120.5%
Aug 5, 2025−$0.53
est −$0.55
+3.6%——−9.0%
May 6, 2025−$0.52
est −$0.56
+7.1%——−15.3%
Feb 25, 2025−$0.61
est −$0.59
−3.4%——−10.1%
Nov 12, 2024−$0.64
est −$0.55
−16.4%——0.0%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Cogent Biosciences stock forecast and analyst price targets

Analysts’ average 12-month price target for Cogent Biosciences is $55.82, +95.4% from the last close, from 8 firms rating the stock in the last 90 days.

$55.82consensus 12-month target, +95.4% from the last close
Low $45High $61
Buy8
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 8 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 12J.P. MorganBuy, maintained$61+113.6%
Nov 9H.C. WainwrightBuy, maintained$56+96.1%
Nov 6WedbushBuy, maintained$55+92.6%
Nov 6Stifel NicolausBuy, maintained$45+57.6%
Oct 27Stifel NicolausBuy, maintained$45+57.6%
+6.1%average 20-day move after past Accumulation readings
−12.5%average move over the next 20 trading days in the last 5 years
±6.5%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Cogent Biosciences seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Cogent Biosciences averaged −12.5% across the last 5 years, rising in 1 of them.

Next 20 trading days, by year

−22.8%2021−1.5%2022−38.6%2023−15.5%2024+20.0%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−5.3%1 of 5
Next 10 trading days−2.2%2 of 5
Next 15 trading days+1.6%3 of 5
Next 20 trading days−12.5%1 of 5
Next 30 trading days−12.3%1 of 5

For scale, COGT’s typical 20-trading-day move in either direction is about 11.5%.

Cogent Biosciences market cap and key statistics

Cogent Biosciences’s market cap is $4.97B and revenue of $0 over the last twelve months.

Valuation

Market cap
$4.97B
EPS, TTM
−$2.26
Gekko Fair Value
$37.57

Trading

Volume
1.15M
Avg volume, 20 days
2.10M
52-week high
$43.73
52-week low
$27.74
Shares outstanding
174.0M

Financials

Revenue, TTM
$0
Profit margin
0%
Return on equity
-99.6%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
0.34
Typical daily move
±6.5%
Typical 20-day move
±11.5%

Cogent Biosciences stock news this week

Coverage of Cogent Biosciences this week reads neutral: 2 positive, 0 neutral and 2 negative headlines.

News sentiment neutral

Cogent Biosciences peers

Cogent Biosciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Cogent Biosciences stock FAQ

What is Cogent Biosciences’s market cap?

Cogent Biosciences’s market cap is $4.97B at the Nov 13, 2026 close of $28.56, with 174.0M shares outstanding.

What is the Cogent Biosciences stock forecast?

The consensus analyst 12-month price target for Cogent Biosciences is $55.82, +95.4% from the last close. Of the 8 firms that rated the stock in the last 90 days, 8 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Cogent Biosciences stock overvalued or undervalued?

On Gekko’s estimate Cogent Biosciences is undervalued: the Nov 13, 2026 close of $28.56 is 24.0% below Gekko Fair Value of $37.57. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Cogent Biosciences report earnings next?

Cogent Biosciences is expected to report on Feb 16, 2027 (93 days away). Analysts expect earnings of −$0.61 per share on revenue of $5.44M. Cogent Biosciences beat the earnings estimate in 4 of its last 8 reports, moving 21.4% on average across the report.

What is Cogent Biosciences’s 52-week high and low?

Cogent Biosciences’s 52-week high is $43.73 and its 52-week low is $27.74; it closed at $28.56 on Nov 13, 2026, −19.0% over the past year.

Is Cogent Biosciences stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Cogent Biosciences the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.